Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 16081
Sealed predictions
- UBE2O in dopamine neurons, braak+0.06 (p 0.873) → +0.04 (p 0.928)receipt 16089
Swarm cases
receipt 16089: UBE2O in dopamine neurons, braak
- power
- full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.881, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.01 (p 0.962, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.11, sign flips 11; without severely affected donors +0.01 (p 0.969, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0072, n 18) vs +0.01 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for UBE2O in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up UBE2O · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.40 p 0.155 (needs p < 1.4e-4)
Receipts
loading the receipts